Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watch this Space: Medtech in the Middle East

This article was originally published in Start Up

Executive Summary

With all the frenzy of investing, partnering, and joint-venturing in emerging markets like China and India, where can medtech investors still get in on the ground floor? The Middle East. While capital for venture firms and their portfolio companies is growing scarcer in the US and Europe, government and private entities operating within the countries of the MENA (Middle East North Africa) region have billions--and in some cases trillions--to invest to further government goals of diversifying local economies beyond oil and real-estate while also improving their health care systems for their growing populations. Now, the former head of direct investment at the Kuwait Investment Authority is establishing a new $150 million investment fund that will focus on life sciences and telecommunications/IT in the region.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091655

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel